11 Managing haematologic manifestations in SLE

The document discusses the management of haematologic manifestations in patients with systemic lupus erythematosus (SLE), focusing on conditions such as anaemia, leukopenia, and thrombocytopenia. Anaemia in SLE can be microcytic, normocytic, macrocytic, or haemolytic, with leukopenia present in up to two-thirds of patients at diagnosis. Thrombocytopenia can occur in various stages and may require aggressive treatment if severe. The document presents three case studies: one where B-cell depletion with rituximab and cyclophosphamide successfully treated low haemoglobin and platelet counts; another involving a patient with refractory haemolytic anaemia who did not respond to rituximab; and a third case of a patient with severe thrombocytopenia and antiphospholipid antibodies, where intensified immunosuppressive therapy and complement inhibition led to improvement. The document emphasizes the importance of distinguishing between medication side effects and disease manifestations, and discusses various treatment options, including the potential role of splenectomy and complement inhibitors.